(Q39547514)

13 September 2017

title

Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models (English)

1 reference

13 September 2017

1 reference

1 reference

Jung-Sun Park

1

1 reference

13 September 2017

Hyun-Jung Sohn

2

1 reference

13 September 2017

Gyeong-Sin Park

3

1 reference

13 September 2017

Yeun-Jun Chung

4

1 reference

13 September 2017

Tai-Gyu Kim

5

1 reference

13 September 2017

language of work or name

1 reference

23 June 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

102

1 reference

13 September 2017

issue

8

1 reference

13 September 2017

page(s)

1448-1454

1 reference

Structure and function of Polo-like kinases

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinases: a team in control of the division

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinases (Plks) and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinase 1 (Plk1) in non-melanoma skin cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Normal cells, but not cancer cells, survive severe Plk1 depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Aurora-A kinase: a novel target of cellular immunotherapy for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Polo-like kinase 1-mediated phosphorylation of the GTP-binding protein Ran is important for bipolar spindle formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: quantitative and qualitative effects of CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01974.X

10.1111/J.1349-7006.2011.01974.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference